Latest Articles

Publication Date
All News Scientific
Engineering the Human Endometrial-Embryo Interface: Breakthroughs in 3D Uterine Models.

Three-dimensional (3D) organoid and co-culture models have emerged as transformative tools for studying human endometrial function, implantation, and placental development, overcoming key limitations of animal and two-dimensional in vitro systems. …

Published: March 3, 2026, midnight
Read Full Article
embryo implantation endometrial epithelial organoids endometrium placenta trophoblast organoids uterus
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Defense World

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Defense World

Published: March 2, 2026, 6:50 p.m.
Read Full Article
Tampons could help early ovarian cancer diagnosis - AOL.com

Tampons could help early ovarian cancer diagnosis AOL.com

Published: March 2, 2026, 6:48 p.m.
Read Full Article
GLP-1–Progestin and Endometrial Cancer Risk - Conexiant

GLP-1–Progestin and Endometrial Cancer Risk Conexiant

Published: March 2, 2026, 5:01 p.m.
Read Full Article
Detecting the body's reproductive hormonal brake against tissue overgrowth: Micrin/SgII-70.

A new humoral factor has been detected, within a project aiming to disclose the body's reproductive hormonal brake against tissue overgrowth, micrin ('my-crin'). Factor purification involved fractionation of ovine and …

Published: March 2, 2026, midnight
Read Full Article
Sarah Maree Cameron on cervical cancer, endometriosis and ADHD - bodyandsoul.com.au

Sarah Maree Cameron on cervical cancer, endometriosis and ADHD bodyandsoul.com.au

Published: Feb. 28, 2026, 9:25 p.m.
Read Full Article
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks

ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon TipRanks

Published: Feb. 27, 2026, 7:47 p.m.
Read Full Article
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat

Published: Feb. 27, 2026, 4:50 p.m.
Read Full Article
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance

Published: Feb. 27, 2026, 4:47 p.m.
Read Full Article
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval - TradingView

ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval TradingView

Published: Feb. 27, 2026, 3:34 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!